Skip to main content
FDA grants accelerated approval to targeted genetic cancer treatment
12/6/2018

Vitrakvi, or larotrectinib, received FDA accelerated approval for treatment of solid tumors with a specific genetic mutation regardless of the type of cancer. "We support innovation in precision oncology drug development and the evolution of more targeted and effective treatments for cancer patients," said Scott Gottlieb, FDA commissioner.

Full Story: